Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00680134 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis

A Phase 2 study, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target

NCT00680134 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00680134, a Phase 2 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target

Study Summary

The purpose of the study is to determine the safety and efficacy of 1% and 5% AN2690 solutions in the treatment of distal, subungual onychomycosis of the great toenail.

Interventions

  • DRUG AN2690

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2006-06-30
Est. Completion 2007-08-31
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00680134

The ClinicalTrials.gov registry entry for NCT00680134 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which AN2690 is the first listed.

NCT00680134 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00680134 about?

NCT00680134 is a clinical study titled "Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis". The purpose of the study is to determine the safety and efficacy of 1% and 5% AN2690 solutions in the treatment of distal, subungual onychomycosis of the great toenail.

What is the current status of trial NCT00680134?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-06-30. Estimated completion is 2007-08-31.

What interventions are being tested in trial NCT00680134?

The interventions under investigation include: AN2690 (DRUG).

Who is sponsoring clinical trial NCT00680134?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.